PLC/PRF/5 Xenograft Model Service for Liver Cancer

The PLC/PRF/5 cell line provides a specialized and highly representative in vivo platform for investigating hepatocellular carcinoma (HCC), particularly for studies involving Hepatitis B virus (HBV) integration. As a premier pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision PLC/PRF/5 Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your liver cancer drug discovery and development pipeline.

Overview of PLC/PRF/5 Xenograft Model for Liver Cancer

The PLC/PRF/5 xenograft model is an established in vivo translational system widely utilized in oncology research for the study of hepatocellular carcinoma. By transplanting human PLC/PRF/5 cells into immunodeficient rodent hosts, this model effectively reproduces the solid tumor growth characteristics, histopathological architecture, and proliferative patterns typical of primary human liver malignancies.

Biologically, the PLC/PRF/5 model is highly valued for its consistent tumor formation and its status as an HBV-positive cell line, which provides a relevant genetic background for studying viral-induced hepatocarcinogenesis. This model preserves key molecular features of HCC, including high proliferative capacity and sensitivity to a wide array of experimental therapeutics. Consequently, the PLC/PRF/5 model is extensively deployed in pre-clinical screening programs to assess the anti-tumor potency of novel small-molecule inhibitors, targeted biological therapies, and combination treatment regimens in a physiologically relevant in vivo setting.

Fig 1. CLSM images of cellular uptake study after treatment of PLC/PRF/5 cells with coumarin-6-entrapped Pull-SA for 4 h at 37℃. (Chirayil TJ., et al., 2022)

Cell Line Information: PLC/PRF/5

The PLC/PRF/5 cell line is derived from human hepatocellular carcinoma tissue and contains integrated HBV sequences. These cells exhibit stable growth characteristics in vitro, making them a reliable and consistent choice for developing reproducible tumor models for cancer research.

Our Services

Workflow of PLC/PRF/5 Xenograft Model Construction

• Cell Culture & Quality Control: Human PLC/PRF/5 cells are expanded in vitro using certified nutrient media under optimized physiological conditions. STR authentication and mycoplasma screening are performed prior to inoculation to ensure absolute genetic integrity and purity.
• Host Selection & Preparation: Immunodeficient mice (e.g., BALB/c nude or NCG) are sourced from validated vendors and acclimatized to facility conditions to stabilize baseline biological metrics.
• Precision Inoculation: A calibrated suspension of high-viability PLC/PRF/5 cells is prepared, often supplemented with an extracellular matrix (e.g., Matrigel) to optimize take rates. Cells are inoculated in vivo via subcutaneous injection into the host flank to facilitate the development of a measurable, solid tumor.
• Longitudinal Monitoring: Tumor dimensions are measured systematically using digital calipers to monitor volume progression. Animal health, activity, and body weight are recorded periodically to document systemic tolerance and clinical status.
• Randomization & Treatment: Once solid tumors reach a predefined, statistically significant volume, animals are randomized into experimental cohorts to ensure baseline parity before the initiation of customized therapeutic dosing regimens.

Fig 2. PLC/PRF/5 Xenograft Model Construction Workflow

Case Study - PLC/PRF/5 Xenograft Model Development

A pre-clinical validation study was conducted using the PLC/PRF/5 xenograft model to evaluate the therapeutic efficacy of a novel anti-HCC candidate. Following the successful subcutaneous inoculation of PLC/PRF/5 cells into immunodeficient mice, the host animals developed firm, rapidly growing solid tumors. The treatment group demonstrated a clear, statistically significant inhibition of tumor growth compared to the vehicle-treated control group, confirming the model's high sensitivity and predictive reliability for screening novel liver cancer interventions.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing diverse solid tumor lineages, providing highly reproducible in vivo translational platforms for liver cancer research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive tumor growth metrics and statistical validations.

Contact us

Accelerating your liver cancer drug pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our PLC/PRF/5 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.